肺淋巴上皮癌(Pulmonary Lymphoepithelial-like carcinoma,pLEC)是一种罕见的非小细胞肺癌(Non-small cell lung cancer,NSCLC),2021 年(World health organization,WHO)将其归类于肺鳞状细胞癌的一个亚型.pLEC的流行病学、临床病理特征、诊断治疗及预后均不同于常见的非小细胞肺癌.pLEC的发生发展和EB病毒(Epstein-Barr virus,EBV)感染密切相关,其预后明显好于常见的NSCLC.近年来有关pLEC的研究有了明显的进展,本文将就pLEC的研究进展进行综述,以促进pLEC的规范化诊断治疗.
Research progress of lung lymphoepithelial carcinoma
Pulmonary Lymphoepithelial-like carcinoma(pLEC)is a rare type of non-small cell lung cancer(NSCLC).In 2021,the World health organization(WHO)classified it as a subtype of lung squamous cell carcinoma.The epidemiology,clinicopathological features,diagnosis,treatment and prognosis of pLEC are different from those of common non-small cell lung cancer.The occurrence and development of pLEC is closely related to Epstein-Barr virus(EBV)infection,and its prognosis is significantly better than that of common NSCLC.In recent years,the research on pLEC has made remarkable progress.This article will review the research progress on pLEC in order to promote the standardized diagnosis and treatment of pLEC.